Unlock instant, AI-driven research and patent intelligence for your innovation.

Methylation marker for auxiliary diagnosis of cancers

An auxiliary diagnosis and methylation technology, applied in the medical field, can solve the problems of long time required for examination, easy to be affected by liver function and cholestasis, low sensitivity of early patients, etc., so as to reduce the effect of diagnosis and treatment.

Pending Publication Date: 2021-08-06
南京腾辰生物科技有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the commonly used clinical diagnostic methods for pancreatic cancer include: (1) imaging methods such as ultrasound, enhanced CT, and magnetic resonance imaging (MRI). Usually, ultrasonography, a method for diagnosing pancreatic cancer, can be used as a supplementary examination of CT, but enhanced CT has a large radiation to the human body, so it is not easy to use frequently; MRI has no radiation effect, but it is not suitable for some people ( There are metal objects and cardiac pacemakers in the body, etc.), the inspection takes a long time, and because the equipment is relatively expensive, some small and medium-sized hospitals have not yet popularized it.
(2) Clinically, some serum tumor markers such as CA19-9, CA242, CA50, etc. will be combined for further detection. The above tumor markers have high sensitivity, but low specificity, and are easily affected by liver function and cholestasis.
(3) Pathological examination: percutaneous biopsy, biopsy guided by ultrasound gastroscope, exfoliated cytology examination of ascites, and exploratory biopsy under laparoscopy or laparotomy, but this method is invasive and not suitable for early stage patients
X-ray barium meal radiography: the patient swallows barium porridge during X-ray examination, observes the development of the barium porridge when it passes through the esophagus, and achieves a qualitative and localized diagnosis. It is affected by the doctor's operation and viewing experience, and this method is not suitable for very early esophageal cancer patient
CT scan: It can show the relationship between the patient's esophagus and adjacent organs, but its disadvantage is that it has low sensitivity for early-stage patients
In addition, there are some commonly used tumor markers, such as CA72-4, CA19-9, CEA, CYFRA21-1 and squamous cell carcinoma-associated antigen (SCC), which can be used for the diagnosis of esophageal cancer, but their sensitivity is less than 40%, and Low specificity, especially low diagnostic value for early-stage patients
However, the correlation between DNA methylation in blood and tumor development is rarely reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methylation marker for auxiliary diagnosis of cancers
  • Methylation marker for auxiliary diagnosis of cancers
  • Methylation marker for auxiliary diagnosis of cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0135] Example 1. Primer Design for Detection of FUT7 Gene Methylation Sites

[0136] After extensive sequence and functional analysis, two fragments (FUT7_A fragment and FUT7_B fragment) in the FUT7 gene were selected for methylation level and cancer correlation analysis.

[0137] The FUT7_A fragment is located in the hg19 reference genome chr9:139924561-139926050, the sense strand.

[0138] The FUT7_B fragment is located in the hg19 reference genome chr9:139926692-139928115, the sense strand.

[0139] The CpG site information in the FUT7_A fragment (SEQ ID No.1) is shown in Table 1.

[0140] The CpG site information in the FUT7_B fragment (SEQ ID No.2) is shown in Table 2.

[0141] Table 1 CpG site information in the FUT7_A fragment

[0142]

[0143]

[0144]

[0145] Table 2 CpG site information in the FUT7_B fragment

[0146]

[0147]

[0148] Specific PCR primers were designed for the two fragments (FUT7_A fragment and FUT7_B fragment), as shown in Tabl...

Embodiment 2

[0151] Example 2, FUT7 gene methylation detection and result analysis

[0152] 1. Research samples

[0153] With the informed consent of the patients, a total of 722 patients with lung cancer, 152 patients with benign nodules in the lungs, 79 patients with pancreatic cancer, 118 patients with esophageal cancer and 945 cancer-free controls were collected. Cancer and no benign nodules in the lungs were reported and blood routine indicators were within the reference range).

[0154] All patient samples were collected preoperatively and confirmed radiographically and pathologically.

[0155] Lung, pancreatic, and esophageal cancer subtypes were judged based on histopathology.

[0156] Lung cancer staging is based on the AJCC 8th edition staging system.

[0157] The 722 cases of lung cancer patients were divided according to the type: 619 cases of lung adenocarcinoma, 42 cases of lung squamous cell carcinoma, 49 cases of small cell lung cancer, and 12 cases of others.

[0158] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a methylation marker for auxiliary diagnosis of cancers. The invention provides an application of a methylated FUT7 gene as a marker in preparation of a product. The application of the product is at least one of the following of auxiliary diagnosis of cancers or prediction of cancer risk; assisting in distinguishing benign nodules and cancers; assisting in distinguishing different subtypes of cancers; assisting in distinguishing different stages of cancers; assisting in distinguishing different cancers; determining whether a to-be-detected object has a hindering or promoting effect on the occurrence of cancers or not, wherein the cancers can be lung cancer, pancreatic cancer or esophageal cancer. The hypomethylation phenomenon of the FUT7 gene in the blood of patients with lung cancer, pancreatic cancer and esophageal cancer is found through research, and the application has important scientific significance and clinical application value for improving the early diagnosis and treatment effect of lung cancer, pancreatic cancer and esophageal cancer and reducing the death rate.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a methylation marker for auxiliary diagnosis of cancer. Background technique [0002] Lung cancer is a malignant tumor that occurs in the epithelium of the bronchial mucosa. In recent decades, its morbidity and mortality have been on the rise, and it is the cancer with the highest morbidity and mortality in the world. Although there have been new advances in diagnostic methods, surgical techniques, and chemotherapy drugs in recent years, the overall 5-year survival rate of lung cancer patients is only 16%, mainly because most lung cancer patients have metastasized and lost surgery. cure opportunity. Studies have shown that the prognosis of lung cancer is directly related to the stage. The 5-year survival rate of stage I lung cancer is 83%, that of stage II is 53%, that of stage III is 26%, and that of stage IV is 6%. Therefore, the key to reducing the mortality of lung cancer patients l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11G16B20/00
CPCC12Q1/6886G16B20/00C12Q2600/112C12Q2600/118
Inventor 王俊狄飞飞韦玉杰
Owner 南京腾辰生物科技有限公司